Atea Pharmaceuticals Inc is a biotechnology business based in the US. Atea Pharmaceuticals Inc shares (AVIR) are listed on the NASDAQ and all prices are listed in US Dollars. Atea Pharmaceuticals Inc employs 63 staff and has a trailing 12-month revenue of around $225 million.
How to buy shares in Atea Pharmaceuticals Inc
- Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – AVIR – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
Atea Pharmaceuticals Inc stock price (NASDAQ: AVIR)Use our graph to track the performance of AVIR stocks over time.
Atea Pharmaceuticals Inc shares at a glance
|Latest market close||$5.60|
|52-week range||$5.31 - $46.91|
|50-day moving average||$7.83|
|200-day moving average||$7.26|
|Wall St. target price||$9.00|
|Dividend yield||$0 (0%)|
|Earnings per share (TTM)||$0.12|
Buy Atea Pharmaceuticals Inc shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Atea Pharmaceuticals Inc stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Atea Pharmaceuticals Inc price performance over time
|1 week (2022-09-23)||-3.45%|
|1 month (2022-08-30)||-26.32%|
|3 months (2022-06-30)||-21.13%|
|6 months (2022-03-30)||-20.90%|
|1 year (2021-09-30)||-84.03%|
|2 years (2020-09-26)||N/A|
|3 years (2019-09-26)||N/A|
|5 years (2017-09-26)||N/A|
Is Atea Pharmaceuticals Inc stock undervalued or overvalued?
Valuing Atea Pharmaceuticals Inc stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Atea Pharmaceuticals Inc's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Atea Pharmaceuticals Inc's P/E ratio
Atea Pharmaceuticals Inc's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 46x. In other words, Atea Pharmaceuticals Inc shares trade at around 46x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
However, Atea Pharmaceuticals Inc's P/E ratio is best considered in relation to those of others within the biotechnology industry or those of similar companies.
Atea Pharmaceuticals Inc's EBITDA
Atea Pharmaceuticals Inc's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $24.6 million.
The EBITDA is a measure of a Atea Pharmaceuticals Inc's overall financial performance and is widely used to measure a its profitability.
To put Atea Pharmaceuticals Inc's EBITDA into context you can compare it against that of similar companies.
Atea Pharmaceuticals Inc financials
|Revenue TTM||$225 million|
|Operating margin TTM||10.92%|
|Gross profit TTM||$184.2 million|
|Return on assets TTM||1.96%|
|Return on equity TTM||2.47%|
|Market capitalisation||$457.9 million|
TTM: trailing 12 months
Atea Pharmaceuticals Inc share dividends
We're not expecting Atea Pharmaceuticals Inc to pay a dividend over the next 12 months.
You may also wish to consider:
- Gilead Sciences (GILD.US) (4.65% forward annual dividend yield)
- GlaxoSmithKline PLC ADR (GSK.US) (8.46% forward annual dividend yield)
- Novartis AG ADR (NVS.US) (4.37% forward annual dividend yield)
Atea Pharmaceuticals Inc overview
Atea Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an antiviral drug candidate that is in Phase II clinical trial for the treatment of patients with COVID-19. The company also develops AT-752, an oral purine nucleoside prodrug product candidate, which has completed Phase Ia clinical trial for the treatment of dengue; AT-777, an NS5A inhibitor; AT-787, a co-formulated, oral, pan-genotypic fixed dose combination of AT-527 and AT-777 for the treatment of hepatitis C virous (HCV); and AT-281, a pharmaceutically acceptable salt for the treatment or prevention of an RNA viral infection, including dengue fever, yellow fever, Zika virus, and coronaviridae viral infection, as well as Ruzasvir, an investigational oral, pan genotypic NS5A inhibitor for the treatment of chronic HCV infection. It has a license agreement with Merck & Co, Inc. for development and commercialization of ruzasvir for the treatment of HCV. Atea Pharmaceuticals, Inc.
Atea Pharmaceuticals Inc in the news
Atea (AVIR) Dengue Candidate Gets Fast Track Designation
Atea Pharma's Investigational Dengue Treatment Fast Tracked In US
Atea Pharmaceuticals Announces U.S. FDA Fast Track Designation Granted to AT-752 for Treatment of Dengue
Frequently asked questionsWhat percentage of Atea Pharmaceuticals Inc is owned by insiders or institutions?
Currently 10.522% of Atea Pharmaceuticals Inc shares are held by insiders and 70.082% by institutions. How many people work for Atea Pharmaceuticals Inc?
Latest data suggests 63 work at Atea Pharmaceuticals Inc. When does the fiscal year end for Atea Pharmaceuticals Inc?
Atea Pharmaceuticals Inc's fiscal year ends in December. Where is Atea Pharmaceuticals Inc based?
Atea Pharmaceuticals Inc's address is: 125 Summer Street, Boston, MA, United States, 02110 What is Atea Pharmaceuticals Inc's ISIN number?
Atea Pharmaceuticals Inc's international securities identification number is: US04683R1068
More guides on Finder
How to buy YanGuFang International Group (YGF) stock when it goes public
Everything we know about the YanGuFang International Group IPO, plus information on how to buy in.
What are the FAANG stocks and how do you invest in them?
Looking to invest in tech? Here’s how to buy shares in the major tech companies, known as FAANG stocks.
How to buy soccer stocks
A simple guide to buying stocks in your favorite European soccer team.
How to buy Juventus stock
Steps to owning and managing JUVE, with 24-hour and historical pricing before you buy.
How to buy AS Roma stock
Steps to owning and managing ASR, with 24-hour and historical pricing before you buy.
How to buy Borussia Dortmund stock
Steps to owning and managing BVB, with 24-hour and historical pricing before you buy.
How to buy Lead Real Estate Co. (LRE) stock when it goes public
Everything we know about the Lead Real Estate Co. IPO, plus information on how to buy in.
How to buy Third Harmonic Bio (THRD) stock
Everything we know about the Third Harmonic Bio IPO, plus information on how to buy in.
How to buy LINKBANCORP (LNKB) stock
Everything we know about the LINKBANCORP IPO, plus information on how to buy in.
Here are the stocks that benefit from inflation, as well as industries to keep an eye on to reduce the impacts of inflation on your portfolio.
Ask an Expert